Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets

Vaccine

Volumn 30, Issue 2, 2012, Pages 237-246

  Cherukuri, Anu ^a   Servat, Esteban ^a   Woo, Jennifer ^a  

^a MEDIMMUNE   (United States)

Author keywords

Antibody secreting cell; Biomarker of immunogenicity; Ferret model of influenza infection; Immune correlate; Live attenuated influenza vaccine

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FERRET; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG PARENCHYMA; MALE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SECRETORY CELL; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MALE; NASAL MUCOSA; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED;

EID: 84355161476     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.001     Document Type: Article

References (24)

1. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24:157-160.
2. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529-549.
3. Ashkenazi S., Vertruyen A., Aristegui J., Arístegui J., Esposito S., McKeith D.D., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
4. Fleming D., Covari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
5. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
6. Zeman A.M., Holmes T.H., Stamatis S., Tu W., He X.S., Bouvier N., et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007, 26:107-115.
7. Sasaki S., He X-S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228.
8. Halliley J.L., Kyu S., Kobie J.J., Walsh E.E., Falsey A.R., Randall T.D., et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 2010, 28:3582-3587.
9. Sasaki S., He X.-S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3(8):e2975.
10. Xu Q., Wang W., Cheng X., Zengel J., Jin H. Influenza H1N1 A/Solomon Island/3/06 virus receptor binding specificity correlates with virus pathogenicity, antigenicity, and immunogenicity in ferrets. J Virol 2010, 84:4936-4945.
11. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3:1541-1555.
12. Chen Z., Wang W., Zhou H., Suguitan A.L., Shambaugh C., Kim L., et al. Generation of Live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84:44-51.
13. Crotty A.R., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286:111-122.
14. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2007, 453:667-671.
15. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13:1006-1012.
16. Murphy B.R., Clements M.L., Madore H.P., Steinberg H., O'Donnell S., Betts R., et al. Dose response of cold adapted reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis 1984, 149:816.
17. Hrabar A., Vodopija I., Andre F.E., Mitchel J.R., Massab H.F., Hennessy A.V., et al. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Dev Biol Stand 1977, 39:53-60. (International symposium on influenza immunization, Geneva).
18. Clements M.L., Snyder M.H., Sears S.D., Maassab H.F., Murphy B.R. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza A/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990, 161:869-877.
19. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R.Z., Chotpitayasunodh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
20. Basha S., Hazenfeld S., Brady R.C., Subbramanian R.A. Comparison of antibody and T cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011, 10.1016/j.humimm.2011.03.001.
21. Lee F.E., Falsey A.R., Halliley J.L., Sanz I., Walsh E.E. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis 2010, 202:1659-1666.
22. Cao Y., Gordic M., Kobold S., Lajmi N., Meyer S., Bartels K., et al. An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. J Immunol Methods 2010, 358:56-65.
23. Lee E.H., Halliley J.L., Walsh E.E., Moscatiello A.P., Kmush B.L., Falsey A.R., et al. Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J Immunol 2011, 186:5514-5521.
24. Kyu S.Y., Kobie J., Yang H., Zand M.S., Topham D.J., Quataert S.A., et al. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods 2009, 340:42-47.